

Antimicrobial Steward Call June 13, 2023

Tennessee Department of Health

Healthcare Associated Infections and Antimicrobial Resistance Program



Welcome



Announcements

AU Reports

- All Reports for Q1 2023 Disseminated
 - TDH AU Point Prevalence
 - AU Quality Report
 - First ever Quarterly SAAR Report

• Deadline for Q2 Data – July 31, 2023

 Follow up for non-reporters from small and critical access hospitals ongoing



SHEA Workshop

- Advancing Health Equity through Antimicrobial Stewardship
- September 6, 2023
- Loews Hotel Atlanta in Atlanta, GA (no virtual option)
- Learning Objectives
 - Describe health inequities as they relate to antimicrobial use, antimicrobial resistance and antimicrobial stewardship.
 - Define gaps and opportunities in antimicrobial stewardship equity.
 - Identify resources available and specific collaborative actions within stewardship teams as well as with other stakeholders aimed at mitigating antimicrobial prescribing inequities.
- Registration is FREE but limited
 - <u>https://learningce.shea-online.org/content/advancing-health-equity-through-antimicrobial-stewardship#group-tabs-node-course-default6</u>







NEW! Quarterly SAAR Report


TN

Quarterly SAAR Report Objective

To create and distribute a meaningful report to facilities comparing SAAR values at the state-level



SAAR QUARTERLY REPORT Q1 | Tennessee, 2023 Statewide SAAR Distribution



SAAR Report




SAAR QUARTERLY REPORT Q1 | Tennessee, 2023

All Antibacterial Agents


- Visualize your facility SAAR values compared to others of similar size
- Compare to benchmark SAAR of 1.0 (observed = predicted use)

All antibacterial agents in the AUR protocol except: AMIKACIN LIPOSOME, CEFIDEROCOL, COLISTIN, DELAFLOXACIN, ERAVACYCLINE, IMIPENEM/CILASTATIN/RELEBACTAM, LEFAMULIN, MEROPENEM/VABORBACTAM, OMADACYCLINE, PIPERACILLIN, PLAZOMICIN, TICARCILLIN/CLAVULANATE




SAAR QUARTERLY REPORT Q1 | Tennessee, 2023

All Antibacterial Agents
All antibacterial agents in the AUR protocol except: AMIKACIN LIPOSOME, CEFIDEROCOL, COLISTIN, DELAFLOXACIN, ERAVACYCLINE, IMIPENEM/CILASTATIN/RELEBACTAM, LEFAMULIN, MEROPENEM/VABORBACTAM, OMADACYCLINE, PIPERACILLIN, PLAZOMICIN, TICARCILLIN/CLAVULANATE







TN

SAAR Categories

- Categories
 - All antibacterial agents
 - Broad-spectrum antibacterial agents used for community-acquired infections
 - Broad-spectrum antibacterial agents used for hospital-acquired infections
 - Antibacterial agents used for resistant gram-positive infections
 - Pediatric all antibacterial agents*
- Locations*
 - ICU
 - Ward
 - Step-down

Feedback and Future Directions

• We would love to hear how you are using these reports at your facility on your stewardship committees

 Please let us know if you have suggestions for additions to this report

Contact: <u>Callyn.Wren@tn.gov</u>





Stewardship Risk Score

Using NHSN Annual Facility Survey Data

- Through an NHSN User Group, TDH has access to facilities' NHSN Annual Hospital Survey
- Information on:
 - Infection Control Practices
 - Microbiology Testing
 - Antimicrobial Stewardship Interventions
 - Others...



Form Approved OMB No. 0920-0666 Exp. Date: 12/31/23 www.cdc.gov/nhsn

Patient Safety Component—Annual Hospital Survey

Instructions for this for	m are available at: <u>http</u> :	//www.cdc.gov/nhsn	/forms/instr/57 103-TOI.pdf	
*required for saving			Tracking #:	
Facility ID:			*Survey Year:	
Facility Characteristics	(completed by Infection	n Preventionist)		
*Ownership (check one):				
For profit	Not for profit, incl	luding church	Government	
Military	Veterans Affairs		Physician owned	
If facility is a Hospital:				
*Number of patient days:				
*Number of admissions:				
For any Hospital:				
*Is your hospital a teaching hospital for physicians and/or physicians-in-training or nursing students?				
If Yes, what type:	□ Major	Graduate	Undergraduate	
*Number of beds set up a	and staffed in the following	g location types (as de	fined by NHSN):	
a. ICU (including adult, pediatric, and neonatal levels II/III, III, or higher):				
b. All other inpatient locations:				
Facility Microbiology Laboratory Practices (completed with input from Microbiology Laboratory Lead)				
*1. Does your facility have its own on-site laboratory that performs bacterial antimicrobial susceptibility testing?				
1a. If No, where is your facility's antimicrobial susceptibility testing performed? (check one)				
Affiliated medical center				
Commercial referral laboratory				
Other local/regional, non-affiliated reference laboratory				



ASP Strategies



Value of Stewardship Interventions

The primary goal of antimicrobial stewardship is to optimize clinical outcomes while minimizing unintended consequences of antimicrobial use, including toxicity, the selection of pathogenic organisms (such as *C. difficile*), and the emergence of resistance.


Which ASP interventions are most effective?



ASP Strategies




Preauthorization vs. PAF



TN

Tamma, et al. Clin Infect Dis. 2017 Mar 1;64(5):537-543.

But what about the others?





Stewardship Risk Score

- Recruiting for workgroup of subject matter experts to help determine
 - Quantify value of each stewardship intervention listed in the NHSN Annual Hospital Survey
- Sending out survey to all stewards in Tennessee, Colorado, and Virginia
 - Expect sometime in July 2023
 - Results to help guide the workgroup



Survey Questions

• For each stewardship intervention:

- On a scale of 1 to 7, with 1 being non-essential and 7 being absolutely essential, how essential is this intervention to the success of your antimicrobial stewardship program?
- On a scale of 1 to 7, with 1 being not effective and 7 being extremely effective, how effective is this intervention at driving antimicrobial use at your facility?






Endocarditis Survey

Management of Endocarditis in Patients Who Inject Drugs in Tennessee

> Jarett Worden, PharmD, BCIDP June 13th, 2023

Background


- Approximately 70,000 Tennesseans are addicted to opioids
- Each day in Tennessee, at least 3 people die from an opioid-related overdose
- Tennessee is ranked 3rd in the country for prescription drug abuse
- Tennessee remains in the top 15 of all states in drug overdose deaths




Background

- Infective endocarditis is a complicated and life-threatening disease
- Approximately 85% of cases of right-sided endocarditis in patients who inject drugs (PWID) and almost 50% of left-sided endocarditis cases are attributed to *S. aureus*
- 10% of all MRSA infections in the US are now attributable to IV drug use
- PWID are 16 times more likely to develop invasive MRSA infections

Background



Demographics (n = 19)




Mental Health Services

& Addiction Management

Addiction Management

Are patients at your facility evaluated for substance use disorders on admission?




of Facilities

Only 4 of 17 facilities (24%) offer Addiction Consultation Service or have Addiction-Trained Clinicians to assist with care


Addiction Management

- 11 (65%) facilities offer inpatient medications to address opioid-withdrawal
 i.e buprenorphine, methadone, or naltrexone ER
- 6 of those 11 (55%) facilities make efforts to ensure continuation of addiction care upon hospital discharge


94% of facilities offer to complete IV antibiotic course inpatient in the hospital




75% of facilities offer to complete IV antibiotic course at a Skilled-nursing facility (SNF)




25% of facilities offer to discharge patient with PICC line to complete IV antibiotic course as Outpatient Parenteral Antibiotic Therapy (OPAT)




50% of facilities offer long-acting lipoglycopeptides at infusion centers (i.e. dalbavancin or oritavancin)




56% of facilities offer to transition to oral antibiotic course prior to or upon hospital discharge




50% of facilities allow patient to leave AMA without continuation of antimicrobial therapy




6% of facilities will discharge patient with PICC line to complete IV antibiotic course as OPAT if patient leaves AMA



38% of facilities offer long-acting lipoglycopeptides at infusion centers if patients leave AMA




88% of facilities will transition to PO antibiotic course prior to or upon hospital discharge if patient leaves AMA



Cardiac Surgery

Cardiac Surgery

• 7 of 16 (44%) facilities perform cardiac surgery for patients with endocarditis



• **6 of 16 (38%)** facilities perform catheter-based interventions (such as AngioVac) for patients with tricuspid valve endocarditis

Summary

- Only ~25% of facilities surveyed offer Addiction Consultation Service or have Addiction-Trained Clinicians
- Majority of facilities offer medications to address opioid-withdrawal
 - Over 50% of those facilities make efforts to ensure continuation upon discharge
- Most of facilities allow patients to complete full IV antibiotic course inpatient or at a SNF
 - Only 1/4 of facilities surveyed allow discharge of PWID with a PICC line to complete IV antibiotics outpatient
- About half of facilities allow patients to transition to long-acting lipoglycopeptides or oral antibiotics to complete antibiotic therapy
- 50% of facilities allow patients to leave AMA without continuation of antimicrobial therapy
- Less than half of facilities surveyed will perform either cardiac surgery or catheter-based interventions for PWID with endocarditis

Congratulations!!!

Kate Miller

\$50 Amazon Gift Card Winner



Management of Endocarditis in Patients Who Inject Drugs in Tennessee

> Jarett Worden, PharmD, BCIDP June 13th, 2023



Project Firstline

Next Steps

- Next Call
 - August 15 2pm Eastern/1pm Central Time
 - Drug Diversion as an Infection Control Breach

- Feedback always appreciated
 - <u>Christopher.evans@tn.gov</u>

